

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 January 2003 (16.01.2003)

PCT

(10) International Publication Number
WO 03/005026 A2

(51) International Patent Classification⁷: G01N 33/53

(21) International Application Number: PCT/GB02/03035

(22) International Filing Date: 1 July 2002 (01.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0116143.9 2 July 2001 (02.07.2001) GB

(71) Applicant (for all designated States except US): AMER-
SHAM BIOSCIENCES UK LIMITED [GB/GB]; Amer-
sham Place, Little Chalfont, Buckinghamshire HP7 9LL
(GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): OSBORN, Nigel,
John [GB/GB]; Amersham Biosciences UK Limited, The
Grove Centre, White Lion Road, Amersham, Bucking-
hamshire HP7 9LL (GB). WILLIAMS, Karen [GB/GB];
Amersham Biosciences UK Limited, The Grove Centre,
White Lion Road, Amersham, Buckinghamshire HP7
9LL (GB). SWEET, Alison, Claire [GB/GB]; Amersham
Biosciences UK Ltd, The Grove Centre, White Lion Road,
Amersham, Buckinghamshire HP7 9LL (GB).

(74) Agents: HAMMER, Catriona, MacLeod et al.; Amer-
sham plc, The Grove Centre, White Lion Road, Amersham,
Buckinghamshire HP7 9LL (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 03/005026 A2

(54) Title: CHEMICAL CAPTURE REAGENT

(57) Abstract: Disclosed is a capture reagent having Formula (I): PRG-L-X-carrier wherein: PRG is a peptide or protein reactive group L is a linker group X is a cleavable group. Also disclosed is a method for selective labelling and purification of proteins and peptides comprising using a capture reagent of Formula (I).

BEST AVAILABLE COPY

CHEMICAL CAPTURE REAGENT

TECHNICAL FIELD

5 The present invention relates to a chemical capture reagent for proteins and peptides. In particular, the invention relates to using a chemical capture reagent in methods of selective labelling and capture of peptides or proteins from samples prior to comparative quantification and analysis.

BACKGROUND TO THE INVENTION

10 It is increasingly being recognised that interpretation of the wealth of new data arising from genomics requires a parallel understanding of the dynamics and differential expression of proteins and peptides themselves. Recent advances in proteomics have
15 focused on developing high throughput methods for rapidly separating and analysing complex protein samples. The most common implementation of proteome analysis is based on the separation of complex protein samples by two-dimensional gel electrophoresis (2DE) and the subsequent sequential identification of peptides, after
20 proteolysis of the separated protein species, by mass spectrometric (MS) techniques.

Although 2DE has considerable resolving power, it has not so far been possible to use this technology to display an entire cell or tissue proteome in a single experiment. Several classes of proteins have proven especially resistant to analysis by 2DE, including
25 low and high molecular mass proteins, membrane proteins, proteins with extreme isoelectric points (pIs) and low abundance, e.g. regulatory, proteins (Corthals *et al.* (2000) Electrophoresis, 21:1104-1115). Some of these proteins escape detection unless prior enrichment steps are taken and this limits the dynamic range of the technique.

30 In addition, the sequential manner in which samples are processed in 2DE-based techniques limits sample throughput and makes automation difficult. Furthermore, the ability to compare differential protein expression by comparative quantitation of proteomes from different samples remains a major challenge in proteomics research.

Accordingly, there is a need for improved techniques which allow the selective labeling and purification of proteins and peptides to facilitate comparative analysis and quantitation.

5

WO 00/11208 describes a method for differential analysis which involves labeling the protein or peptide samples in solution with an isotopically-coded affinity tag (ICAT™). To compare protein abundance between two proteomes quantitatively, one proteome is treated with a 'light' (non-deuterated) version of the affinity reagent and a second
10 proteome is treated with a 'heavy' (deuterated) version of this probe. Following trypsin digestion, the affinity reagent-labelled peptides are isolated by (strept)avidin chromatography and analysed by liquid chromatography MS. The ICAT™-affinity reagent (~500Da) is a relatively large modification that remains on each peptide throughout the MS analysis.

15

However, in order to analyse the isolated proteins or peptides, the strong affinity bond between the ICAT™ reagent and solid phase must be disrupted. Disrupting such affinity interactions often requires forcing conditions, which may cause damage to the protein or peptide sample prior to analysis or may result in low recovery yields of the sample.

20

Moreover, the affinity reagent must be added in excess to ensure that all the protein is labelled and excess affinity support must be present to ensure that all labelled protein then binds. This method therefore requires a high level of sample manipulation with two separate steps to label and capture the desired proteins/peptides. Furthermore, where the affinity approach is used, non-specific binding between proteins/peptides in the sample
25 and the affinity reagent on the solid surface may occur. In addition, endogenous biotin binding proteins in the sample may bind directly to a streptavidin-coated solid surface. This may give false results in an analysis and complicate the binding reaction.

30

WO 01/86306 describes a method for differential analysis of proteins. The method involves fragmenting differentially expressed protein samples, either enzymatically or chemically, to produce a peptide pool. A proportion of this peptide pool is then

isotopically labelled, for instance on cysteine using a thiol-reactive reagent coupled to an affinity reagent such as biotin. The resultant peptides are then captured using a capture moiety and subsequently analysed by mass spectrometry. Mention is also made of the possibility of selectively labelling the N-, C- or both termini.

5 Zhou *et al.* (Nature Biotechnology (2002) 19, 512-515) describes methodology for differential analysis of a protein reactive group coupled to a linker itself bound to aminopropyl glass beads via a photochemically cleavable group. The paper describes only the use of cleavage via photochemical means.

10 Munchbach *et al.* (Analytical Chemistry (2000), 72, 4047-4057) describes an alternative strategy for differential analysis of proteins. Blocking of the lysine residues is achieved using succinic anhydride, followed by proteolysis, to liberate peptides whose N-termini can be subsequently labelled with either H4 or D4 1-(nicotinoyloxy)succinimide and the
15 two samples then combined. The presence of the positive charge on labelled proteins under acidic conditions aids subsequent analysis by mass spectrometry.

US 4331590 describes a binding assay for determination of the concentration of a ligand in a liquid medium based on a conjugate of the form glycone-dye indicator-ligand.

20 Subsequent determination of the label is achieved after enzymatic cleavage of the glycosidic linkage between the glycone and the dye moiety resulting in an increase in the fluorescence. Separation of bound from non-bound components is achievable using a variety of different methods such as a solid-phase bound antibody as well as the use of immune complex precipitating agents and adsorbents. The separation is by affinity means
25 rather than covalent.

An alternative strategy was devised by Smith (Analytical Chemistry (2001) 73, 2132-2139) where ¹⁵N-metabolic labelling was used to introduce labels into proteins.

Iodoacetyl-poly ethylene oxide-biotin was then used to label the cysteine-containing
30 proteins, the sample then being hydrolysed by trypsin. Cysteine-containing peptides were then isolated using immobilised avidin.

WO 02/42427 describes the use of protein mass tag reagents (PMT) that allow for selective isolation of either peptides or protein fragments from complex mixtures either with or without the digestion of the proteins. The PMT consists of at least an amino acid reactive moiety plus possibly one or more accessory moieties and/or one or more recognition moieties, the mass difference part of the compound being present at the amino acid reactive, accessory or recognition moiety. The accessory moiety may be a fluorescent chemical functionality or an entity that enhances separation of the proteins or peptides by the PMT reagents. In addition the labelling of proteins after proteolysis with a biotin- moiety containing an isotopic label is discussed.

Many of the methods in the art depend upon the use of affinity reagents (e.g. WO 00/11208, WO 01/86306, US 4331590, WO 02/42427) for the capture and/or purification of peptides or proteins. The use of such affinity reagents necessitates additional handling/purification steps and may lead to binding of endogenous biotin containing peptides (e.g. acetyl CoA carboxylase) and non-specific adsorption. Indeed, quantitative cleavage of biotin-labelled peptides from affinity columns can prove difficult. The disruption of affinity bonds in such methods, and the use of photochemical energy in the Zhou method described above, may also cause protein/ peptide damage. Furthermore, few of these methods are amenable to the analysis of hydrophobic proteins

There is therefore a need for an improved method.

The present invention involves the capture of proteins and/or peptides onto a carrier, such as a solid support, using a reagent which is covalently bonded to immobilise it onto the carrier and has a protein reactive group itself covalently connected to a linker containing a label, and a cleavable group. This allows the labelling and capture step to be combined in a single step by incubating the protein or peptide with the single reagent and provides protein or peptide attachment to a solid phase by covalent, chemical means (so-called "chemical capture") rather than through an affinity interaction.

For the analysis of multiple protein samples in a differential approach, it is desirable to minimise the manipulations of each sample to maintain the original protein representation. Using the chemical capture approach of the present invention, the individual sample manipulation is reduced, requiring only a single step to label and capture the desired proteins/peptides by mixing each sample with the relevant solid support-bound reagent. The captured samples can then be combined, enabling all subsequent steps to be carried out on the mixed solid-support samples. This ensures that uniform treatment is applied to the two (or more) samples such that any differences observed are as a result of different protein expression levels and turnover rates in the samples rather than as a result of variations in the processing of the individual samples.

For MS analysis, as the chemical capture reagent relies on a covalent linkage with the solid phase and a cleavable linker rather than an affinity interaction, the molecular weight of the peptide and label together can be reduced because the sample is cleaved from the solid support leaving only the label attached to the protein / peptide, compared to an affinity approach where the labelled sample also includes the mass of the affinity group itself. This is advantageous as the resolution of MALDI and electrospray mass spectrometers is generally higher at lower molecular weight, thus a smaller label/modification is preferable.

SUMMARY OF INVENTION

The present invention provides a capture reagent having Formula (I):

PRG-L-X-carrier (I)

wherein:

PRG is a peptide or protein reactive group

L is a linker group

X is a cleavable group

Suitably, PRG may be any functional group that reacts selectively with any functional groups present in specific peptides or proteins. In a particularly preferred embodiment, the functional group targeted is cysteine residues and the PRG is selected from the group consisting of maleimide, pyridyldisulfide, vinylsulfone, iodoacetamide, epoxide, nitrile, aryl thiol, or sulfonated alkyl, in order to capture thiol containing proteins or peptides. In a particularly preferred embodiment the PRG is maleimide.

Several other functionalities exist on a protein or peptide that could also be specifically targeted e.g. ϵ -amino groups on lysine residues or the N-terminus of a peptide or protein could be targeted by active esters, such as N-hydroxysuccinimide ester, by isothiocyanates, isocyanates, imidoesters or sulphonyl halides as the PRG. Amines may also be specifically targeted with aldehydes and ketones in the presence of a reducing agent such as sodium borohydride or sodium cyanoborohydride.

Carboxylic acid residues on amino acids, such as glutamic acid or aspartic acid, or the C-terminus of an amino acid may be coupled to either amines or alcohols, for example using water soluble carbodiimides, such as the carbodiimide 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC) with or without the presence of catalysts such as 4-dimethylaminopyridine.

Phosphate-containing peptides (e.g. phosphoserine or phosphothreonine-containing peptides) can be modified by first treating them with barium or sodium hydroxide (see, for example, Oda *et al.* (2001) *Nature Biotech*, 19, 379-382 and Byford MF, *Biochem J*, (1991) 280, 261-265) to effect elimination of the phosphate groups to leave an alkene group. The resultant alkene can be reacted directly with a carrier thiol functionality as the PRG or further treated with an excess of ethane dithiol to form a thiol group for binding to a maleimide or other thiol-reactive PRG.

For carbohydrate-containing proteins or peptides, suitable PRGs include amines or hydrazines which may react with aldehydes or ketones present on the carbohydrate with or without the presence of a dehydrating agent such as 2, 2-dimethoxypropane followed

by reduction of the resultant Schiff base with NaBH_4 , or NaCNBH_3 . Alternatively, oxidation of vicinal diols on the carbohydrate can be achieved, for example, with periodic acid and the resultant aldehyde coupled to an amine- or hydrazine-based linker.

5 The PRG may be chosen so as to covalently target a reaction with specific protein functions such as enzyme classes. For example, PRG may be based on inhibitors of specific enzyme classes such as kinases, phosphatases or proteases. Thus, in one embodiment, PRG may be based on a mechanism-based or suicide inhibitor. Such inhibitors (reviewed for example in Sandler *et al.*, "Design of enzyme inhibitors", Oxford
10 Science Publications 1989 (ISBN 0-19-261537-8) and Walsh (1984) *Ann. Rev. Biochem* 53, 493-535) can display remarkable specificity for a particular enzyme or class of enzyme. For example, serine hydrolases are potently inhibited as a class of enzymes by fluorophosphonates as well as groups bearing α -halo or (acyloxy)methyl ketone substituents (Cravatt & Sorensen (2000), *Curr. Opin Chem Biol.*, 4:663). Tyrosine kinase
15 can be inhibited with 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido (Smaill *et al.*, (2000) *J Med Chem.* 43(7), 1380-1397). Binding interactions between a PRG and different classes of enzymes are described, for example, by Cravatt and Sorensen. In another embodiment, PRG may be an enzyme substrate that is selectively cleaved or modified by the enzyme of interest rendering the enzyme bound to the capture reagent.

20


L is a linker group which is, preferably, substantially unreactive to peptides and proteins and to cleavage conditions. Suitable linker groups include: ethers, polyethers, amides, polyamides, polythioethers, disulfides, silyl ethers, methyl, alkyl or alkenyl chains (straight chain or branched and portions of which may be cyclic) aryl, diaryl or alkyl-aryl
25 groups. In the context of the present invention, the term alkyl is to be interpreted as comprising 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms. More preferably, the linker group L is a C_4 or a C_6 alkyl group. Aryl groups in linkers can contain one or more heteroatoms (e.g. N, O or S atoms).

Suitably the linker group comprises a detectable label moiety and is covalently linked to a cleavage group such that cleavage of the cleavable group results in the detectable label moiety remaining bound to the PRG and the captured protein or peptide.


- 5 In one embodiment, at least some of the atoms in the linker or the cleavable group may be readily replaced with stable heavy isotopes, for example, hydrogen may be replaced by deuterium. Different combinations of hydrogens and deuteriums may be used to enable multiple samples to be differentially labelled and detected by mass spectrometry. Suitably, at least 2 deuteriums but preferably 6 to 8 deuteriums are included where mass
10 spectrometric detection is used.

Particularly preferred linkers using stable heavy atoms include those given by the following Formulae V-IX in which H/D indicates where the Hydrogen atoms (H) may be readily replaced with Deuterium (D).


V




VI




VII



VIII



IX



In another embodiment, L may comprise a detectable label moiety. Suitable label moieties include stable isotopic labels such as ^2H , ^{13}C , ^{15}N , ^{17}O , ^{18}O , ^{34}S , ^{33}S , ^{36}S ,
 5 radioisotopic labels e.g. ^3H , ^{14}C , ^{35}S or chromophores, such as an azo dye, fluorophores such as fluorescent dye molecules or luminescent molecules. Particularly preferred fluorescent dye molecules include fluoresceins, rhodamines, coumarins, cyanine dyes (CyDyesTM), BODIPYTM dyes and squarate dyes.

Suitably, the detectable label exists in at least two distinguishable forms enabling quantitative differential analysis between two or more samples to be performed. In a particularly preferred embodiment, the distinguishable forms have substantially the same chemical structure such that two samples labelled with two distinguishably labelled capture reagents have substantially indistinguishable mobility when analysed by chromatography or other separation methods such as 2DE, capillary electrophoresis (CE).

In a particularly preferred embodiment, the linker comprises a fluorescent moiety. In this embodiment, carrier reagents for use in determining differential expression of proteins in two samples would comprise linkers containing spectrally resolvable fluorescent dye molecules. Sets of "matched" luminescent dyes i.e. dyes having generally the same size, ionic and pH characteristics but that absorb and/or fluoresce light at different wavelengths are described, for example, in US 6,043,025.

In a particularly preferred embodiment for mass spectrometric detection, distinguishable labels would comprise differentially isotopically labelled linkers that give a mass difference that can be resolved in the mass spectrometer.

The linker may also comprise additional modifications to enhance ionisation in the mass spectrometer. Depending on the nature of the PRG, the modification may include the addition of an acidic or basic group, e.g., COOH, SO₃H, primary, secondary or tertiary amino groups, ethers, nitrogen-heterocycle or specific combinations of these groups can be employed in the linker to promote ionisation. Alternatively, the linker may also contain groups having a permanent charge, e.g., phosphonium groups, quaternary ammonium groups, tetralkyl or tetraryl borate, trityl, sulfonium groups, chelated metal ions, or stable carbanions to enhance ionisation of the labelled species. Other suitable linker groups include trityl (triphenylmethyl) groups described, for example, in WO99/6007.

X is a chemical group that may be cleaved specifically to release the protein/peptide sample from the carrier molecule whilst leaving the label attached to the sample.

Cleavage may be achieved by a number of different strategies, notably by acidic or basic treatment, by photochemical or thermal means, by enzymatic cleavage, by electrochemical, reductive, nucleophilic or electrophilic cleavage. Suitably, the cleavable group, X, is positioned such that, following a cleavage reaction, the label in the linker group, L, remains bound to the captured protein or peptide. It will be understood that following protein or peptide capture, cleavage may result in X remaining attached either to the carrier (i.e. the L-X bond being cleaved) or to the linker group L (i.e. the X-carrier bond being cleaved).

A number of different cleavable functionalities could be envisaged. For example, acid cleavable groups have been described by Floersheimer (Peptides, p131-132, 1991) and Mergler (Tetrahedron Letts. (1998) 29, 4005-4012). These are cleavable using 1% trifluoroacetic acid in a suitable solvent. Other acid labile groups have been described by Albericio (Tetrahedron Letts. (1991) 32, 1015-1018) and include groups which are cleavable with 0.1% trifluoroacetic acid. A similar approach to linker cleavage was employed by Rink (Tetrahedron Letts. (1987) 28, 3787-3790) where the labile group is cleavable in 10% acetic acid.

Base labile linkage groups have been described (Liu, Int J Pept Protein Res. (1990) 35, 95-98) together with the cleavable group described by Albericio (Tetrahedron Letts. (1991) 32, 1515-1518) which cleaves through a β -elimination process using piperidine or diazabicyclo-[5.4.0]undec-5-ene (DBU).

Groups cleavable with fluoride ions have also been developed and are described, for example by Ramage (Tetrahedron (1992) 48, 499-514) and Mullen (Tetrahedron (1987) 28; 491-494). Reductive cleavage of the group is possible with ammonium formate/palladium catalysed hydrogenolysis (see, for example, Anwer (1981) Tetrahedron Letts., 22, 4369-4372) whereas reductive cleavage of a 2-azidomethyl-4-hydroxy-6,N-dimethylbenzamide moiety requires triphenylphosphine (Robinson (1993) Tetrahedron 49, 2873-2884).

A nitrobenzophenone based cleavable group such as that described by Findeis (J Org Chem. (1989) 54, 3478-3482) and Kaiser (Science (1989) 243, 187-191) can be cleaved —nucleophilically using amines, hydrazine and carboxylic acids.

- 5 In another embodiment, for mass spectrometric detection the cleavable group itself may be differentially labelled using heavy atoms, such as deuterium, or stable isotopes such that cleavage results in the label remaining bound to the captured protein or peptide.

Suitably the cleavable group, X, is covalently attached to the carrier which comprises, or
10 may be functionalised to comprise, a reactive group. For example, X may comprise an activated carboxylic acid (such as NHS ester) while the carrier may comprise an amine (or vice versa). Other suitable pairs which can form covalent bonds in this way include epoxide - nucleophile (e.g. amine, thiol or alcohol) to form an ether linkage, maleimide -

- 15 thiol and boronic acid - 1,2-diol (e.g. 1,2- dihydroxyethane and other dihydroxyalkanes). In a particularly preferred embodiment, the cleavable group, X, is attached to the carrier via 1-carboxymethyl-3-formyl indole.

It is preferred that the components of the compound of Formula I are selected to enable peptide or protein capture to occur such that peptide/protein coupling to the PRG can
20 occur under conditions where the cleavable moiety X is stable. Cleavage at X can occur under conditions that leave L-PRG-peptide/protein intact. Suitably, where a hydrogen/deuterium label is present, the reaction conditions must be such that there is no detectable proton exchange reaction between exchangeable protons in the linker group and the solvent during any of the sample manipulations.

25

In one embodiment, the carrier may be a solid support. Suitably the solid support is particulate i.e. of a nature suitable to give a high surface area for protein / peptide capture.

- The solid support could be a number of different types, with varying functionalities. For
30 example Sepharose (e.g. Sepharose 6B) based solid supports containing carboxy, amine, thiol, epoxy, cyanogen bromide, hydrazide and N-hydroxysuccinimide esters as the

coupling functionality (e.g. NHS-activated Sepharose, CNBr-activated Sepharose (Amersham Biosciences). Toyopearl epoxy resin (TosoHaas) or Controlled Pore Glass (CPG) with aminopropyl, aminoaryl, N-hydroxysuccinimide ester, glyceryl, hydrazide, alkylamine, thiopropyl functionality present may also be employed. The pore size of the solid support could be used to discriminate between various sizes of protein. Silica-based solid supports e.g. CombiZorb S (Agilent Technologies) are functionalised with either a triamine or monoamine which could be used as a handle for further derivatisation.

Suitably, the density of protein reactive groups on the solid phase is such that an excess of solid phase-bound PRGs may be used to ensure that the reaction kinetics are in favour of bound peptide, with any excess PRG being quenched once the reaction has gone to completion. The loading of the solid support with the protein reactive groups is dependent on the starting density of functional group on the solid support used to prepare the chemical capture reagent. The density or substitution level of a functional group on the solid support is generally quoted in $\mu\text{moles per gram}$ of dry solid support. Substitution levels for functional groups vary widely from around $800\mu\text{mol/g}$ for Toyopearl epoxy resin to $19\mu\text{mol/g}$ for epoxy functionalised Sepharose 6B. However, where the PRG on the solid support is thiol reactive, targeting proteolytic digests, then only a small proportion of the peptides would be expected to bind given that less than 5% of amino acids are cysteine. Accordingly, in one preferred embodiment, the density of the functional groups on the carrier is in the range of 1 to $100\mu\text{mol/g}$.

For fluorescence detection, it would be desirable to be able to control the number of labels added to each protein molecule to give consistent labelling for analysis of whole proteins. Standard fluorescent labelling methods using activated or reactive dyes targeted at specific amino acid residues result in a distribution of labels on the target protein. In one embodiment, where the linker comprises a fluorescent moiety, the density of the protein reactive groups on the solid phase could be used to control the number of labels attached to each protein molecule. In a particularly preferred embodiment, this would enable stoichiometric labelling of the protein sample resulting in one label per protein molecule to allow true quantitation of protein abundance in a sample.


In addition magnetic beads, latex, agarose or any biopolymer could also be envisaged as potential supports for the chemistry. Chemisorption can also be applied to the immobilisation of biopolymers on a surface (Bioconjugation, 1st Edition, Dent and Aslam; 531-553). A large number of different functionalities, listed in this publication, are available commercially.

In another embodiment, the carrier may be a water soluble carrier or macromolecule which is also, preferably, chemically stable. Suitable soluble macromolecules include polyethylene glycol (PEG), such as PEG-based solid supports containing N-hydroxysuccinimide ester, aldehydes, maleimides, and mPEG-BTC (Harris, Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications p1-14 Plenum press). Other suitable soluble macromolecules include copolymers of HPMA (N-(2-hydroxypropyl) methacrylamide) and acrylamide-based molecules with PEG linkers. Still further water soluble macromolecules include Dextran T-40 (Amersham Biosciences), Ficoll PM70 (Amersham Biosciences), Polyethylene glycol (Fluka), Polypropylene glycol (Fluka), Poly-L-lysine hydrobromide (Fluka), Polyvinyl alcohol (Fluka), Chitosan (Aldrich), Polyethylenimine (Aldrich), Polyallylamine (Aldrich), Poly(dimethylamine-co-epichlorohydrin) (Aldrich), Starburst PAMAM dendrimers (Aldrich) and DAB-Am polypropylenimine dendrimers (Aldrich). In a preferred embodiment, the water soluble linker comprises Ficoll PM70.

The advantage of using such a soluble macromolecule is that it is more compatible with chromatographic separations for washing to remove uncaptured peptides and elution after cleavage.


In a particularly preferred embodiment, there is provided a capture reagent of Formula II:

FORMULA (II)




In another preferred embodiment, there is provided a capture reagent of Formula III:

5 FORMULA (III)



In a further preferred embodiment, there is provided a capture reagent of Formula IV:

10 FORMULA (IV)



In a second aspect of the invention, a method for making a capture reagent in accordance with the first aspect is provided. The method of generating a capture reagent PRG-L-X-carrier can be achieved in several ways. Suitably, said method may comprise first synthesising a compound having the formula PRG-L-X prior to coupling it directly with a functionality on the carrier. Alternatively, the method may comprise attachment of the cleavable group, X, onto the carrier followed by sequential addition of the groups L- PRG or L, or PRG. It is important to cap excess amino functionalities on the carrier molecule prior to the removal of the protecting group.

- 10 In a third aspect of the invention there is provided a method for selective labelling and purification of proteins and peptides comprising the steps of:
- a) providing a capture reagent in accordance with the first aspect of the invention to a sample containing proteins or peptides under conditions to promote attachment of the proteins or peptides to the PRG;
 - 15 b) releasing captured components from the carrier; and
 - c) detecting and identifying the released components.

- In a fourth aspect of the invention, there is provided a method for selective labelling and purification of proteins and peptides in one or more samples containing mixtures of proteins or peptides comprising the steps of:
- 20
- a) providing a capture reagent in accordance with the first aspect of the invention to one or more samples containing proteins or peptides under conditions to promote attachment of the proteins or peptides to the PRG, wherein the detectable label of the capture reagent provided to one sample is distinguishable from that provided to another;
 - 25 b) releasing captured components from the carrier; and
 - c) detecting and identifying the released components.

Optionally, the method further comprises a pre-treatment step wherein functional groups on the protein or peptide are modified to render them reactive with the protein reactive group PRG prior to conducting step a) above. In one embodiment, the modification

30

comprises treatment of carboxylic acid groups on the peptide or protein with a water soluble carbodiimide, such as the carbodiimide 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC) with or without the presence of catalysts such as 4-dimethylaminopyridine.

5

In another embodiment, the modification comprises elimination of phosphate groups on the peptide or protein to leave a reactive alkene group which, optionally, may be converted to a thiol group. The alkene group can be reacted directly with a thiol functionality as the PRG; if converted to a thiol group, this can in turn be bound to maleimide or other thiol-reactive PRG.

10

In the case of carbohydrate-containing proteins or peptides, the modification may comprise oxidation of vicinal diol groups or dehydration and reduction of aldehyde or ketone groups. These groups will react with amine or hydrazine functionalities of the PRG.

15

Suitably, the samples may be derived from multiple different protein samples, for example, different cell types, cells subjected to different treatments or healthy and diseased cells, in order to make a comparison of the proteome in the two or more samples.

20

Accordingly, in one embodiment of the fourth aspect the method further comprises the step:

d) measuring the relative abundances of the released components derived from each sample.

25

Suitably the method allows determination of differences in protein content of the samples such as relative expression levels of proteins.

30

Preferably, in either the third or fourth aspects of the invention, the proteins or peptide components in the samples are pre-treated, for example enzymatically (e.g. subjected to

proteolytic degradation with trypsin) or chemically processed, before or after their capture. The samples may also be fractionated prior to capture. In one embodiment, protein samples may be reduced or subjected to proteolysis prior to capture. In another embodiment, peptide components may be treated so as to ensure oxidation of N-terminal serine or threonine functionalities. In this embodiment, proteolytic degradation of protein samples is followed by, for example, periodate treatment. Oxidised samples can then be specifically coupled to a carrier with, for example, an aminooxy protein reactive group (Gaertner (1996) Bioconjugate Chemistry 7, 38 - 44).

10 In a particularly preferred embodiment captured components derived from different samples may be combined prior to releasing all captured components.

In another embodiment, proteins bound to the capture reagent are treated by enzymatic or chemical reaction and unbound peptides removed by washing. Preferably, washing to
15 remove unreacted or non-specifically bound proteins or peptides can take place before or after mixing of the two samples.

The mode for releasing captured components from the carrier depends on the nature of the cleavable group, X. Preferably cleavage of the interaction is by chemical, pH,
20 enzymatic or photochemical means.

In one embodiment of either the third or fourth aspect of the invention, an additional separation step can be performed before the detection step c). Suitably, the separation step may be by high performance liquid chromatography, e.g. on a C18 reverse phase
25 column, ion exchange chromatography, gel filtration or hydrophobic interaction chromatography, or by electrophoretic methods e.g. capillary electrophoresis, 1D or 2D gel electrophoresis. The separation step may also possibly be a multidimensional or parallel purification.

Where the capture reagent comprises a fluorescent label moiety, the proteins labelled with fluors preferably would be separated by 2D or 1D electrophoresis followed by excision and digestion of proteins of interest, or by capillary electrophoresis.

5 It will be recognised that the method of detection in step c) depends on the nature of the label moiety which is included in the capture reagent. Preferably, the method of detection and identification of the released components in step c) is a mass spectrometric method such as MALDI or electrospray mass spectrometry. In another embodiment, the method of detection may be a fluorescent detection technique such as
10 use of a CCD camera or fluorescent scanner or fluorescent lifetime.

Methods and instrument control protocols for the analysis of peptides by mass spectrometry are well-known in the art and described, for example, in Ducret *et al.* (Prot. Sci. (1998) 7, 706-719); Figeys & Aebersold (Electrophoresis (1998), 19, 885-892);
15 Figeys *et al.* (Electrophoresis (1998), 19, 1811-1818); and Haynes *et al.* (Electrophoresis (1998) 19, 939-945).

Both the quantity and sequence identity of the proteins from which the tagged proteins originated can be determined by automated multistage MS. This is achieved by the
20 operation of the mass spectrometer in a dual mode in which it alternates in successive scans between measuring the relative quantities of peptides eluting from the capillary column and recognising the sequence information of selected peptides. Peptides are quantified by measuring in the MS mode the relative signal intensities for pairs of peptide ions of identical sequence that are tagged with the isotopically light or heavy forms of the
25 reagent, respectively, and which therefore differ in mass by the mass differential encoded within the tagged reagent. Peptide sequence information is automatically generated by selecting peptide ions of a particular mass to charge ratio for collision induced dissociation in the mass spectrometer. The resulting spectra are then automatically correlated with sequence databases to identify the protein from which the sequenced
30 peptide originates. Combination of the results from MS analyses of tagged and differentially labelled peptide samples therefore determines the relative quantities as well

as the sequence identities of the components of protein mixtures in a single, automated operation.

5 In a fifth aspect of the invention, there is provided a use of a capture reagent in accordance with the first aspect in analysis of proteomes (or parts of the proteome) from two or more different samples.

In another aspect of the invention, there is provided a use of a capture reagent in accordance with the first aspect in separation of two or more peptides.

10

In a sixth aspect of the invention there is provided a kit for use in the analysis of proteomes, said kit comprising a capture reagent in accordance with the first aspect.

Preferably, such a kit comprises at least two individually identifiable capture reagents.

15 For example, one with hydrogens present in the linker and one with deuteriums, such that the kit can be used to measure the relative quantities of proteins from at least two different samples.

20 Following chemical capture and separation, each proteome sample has the potential to create many hundreds of fractions of peptides requiring analysis with even more complexity being required if sequencing of each peptide is necessary. The workflow of different embodiments of the invention are shown in Figures 2 to 4. Where the reporter molecule is a fluorescent moiety, the proteolysis step is removed and purification and analysis would normally be performed by 2D-gel electrophoresis. For solution phase
25 labelling of peptides a soluble macromolecule carrier is used (Figure 4).

For example, where isotopically labelled chemical capture reagents are used, the repetitive steps that are involved in large scale sample analysis include the collection of isotope-labelled peptides from the chromatography column, spotting these onto the
30 appropriate target depending on the choice of mass spectrometer (e.g. the MALDI target together with matrix where this is the mass spectrometer of choice) and analysis of each

fraction. Automation of this part of the process would increase both the throughput and accuracy of the collected data.

Accordingly in a seventh aspect of the invention there is provided an automated system
5 for analysis of proteomes. For mass spectrometric detection of isotopically labelled samples, a suitable automated system may comprise use of a capture reagent in accordance with the first aspect of the invention, automated steps of HPLC and an in-line fraction collector and spotter.

10 Strategies for automation in the case of MALDI MS could, for example, involve collection of the samples from the chromatographic separation in a microtitre plate, or reducing the flow rate using microbore HPLC. Alternatively, where electrospray is the analytical method of choice, thermo ion spray could be used to concentrate the sample as it exits the column.

15

Brief Description of the Drawings

For the purposes of clarity, certain embodiments of the present invention will now be described by way of example with reference to the following figures:

20

Figure 1 shows a reaction scheme for preparation of a compound of Formula II;

Figure 2 shows a reaction scheme for relative peptide quantification by chemical capture of proteins followed by proteolytic digestion;

25

Figure 3 shows a reaction scheme for relative peptide quantification by chemical capture of peptides following proteolytic digestion of protein samples;

30

Figure 4 shows a reaction scheme for solution phase labelling of proteins with a soluble carrier;

Figure 5 shows a reaction scheme for the preparation of Maleimidocaproic acid-Sieber-CPG functionalised solid support;

Figure 6 shows a reaction scheme for the preparation of Maleimidocaproamide-Rink-CPG

Figure 7 shows a reaction scheme for the preparation of Maleimidocaproamide-Indole-Aminomethylated Polystyrene

Figure 8 shows an HPLC trace of 6-Maleimidocaproamide (hard line denoting absorption at 215nm, dotted line denoting absorption at 256nm);

Figure 9 shows a calibration curve of HPLC integration against mass of Maleimidocaproamide;

Figure 10 illustrates the kinetics of cleavage of Maleimidocaproamide acid from Maleimidocaproamide-Sieber-CPG;

Figure 11 shows an HPLC trace for a Creatine Kinase-Trypsin digest (hard line denoting absorption at 215nm, dotted line denoting absorption at 256nm);

Figure 12 shows a MALDI mass spectrum of chemically captured and cleaved Creatine Kinase on Maleimidobutyramide-Sieber-CPG;

Figure 13 depicts the normalised cleavage of Maleimidobutyramide from Maleimidobutyramide-Sieber-CPG;

Figure 14 shows a calibration of H₆ and D₆ Maleimidobutyric acid and concentration;

Figure 15 shows a MALDI mass spectrum of chemically captured and cleaved Glyceraldehyde 3-Phosphate Dehydrogenase on Maleimidobutyramide-Sieber-CPG;

Figure 16 shows a mass spectrum depicting 1:4 (H:D) capture of Laminin Peptide 925-933 on H₆ and D₆ Maleimidobutyramide-Sieber-CPG (shown with sodium adduct);

5 Figure 17 shows a MALDI mass spectrum depicting 1:1 (H:D) capture of Laminin Peptide 925-933 on H₆ and D₆ Maleimidobutyramide-Sieber-CPG (shown with sodium adduct);

Figure 18 shows a MALDI mass spectrum depicting 4:1 (H:D) capture of Laminin
10 Peptide 925-933 on H₆ and D₆ Maleimidobutyramide-Sieber-CPG (shown with sodium adduct);

Figure 19 shows a comparison of experimentally derived and the theoretical ratio of
D₆:H₆-Maleimidobutyramide-Laminin;

15

Figure 20 shows a MALDI mass spectrum of chemically captured and cleaved [Val-OH]-
α-Melanocyte Peptide on NHS-Adipic acid-Sieber-CPG; and

Figure 21 shows a MALDI mass spectrum of chemically captured and cleaved Bag Cell
20 Peptide 1-8 on NHS-Adipic acid-Sieber-CPG.

DETAILED DESCRIPTION OF THE INVENTION

25

Abbreviations

In the interests of brevity, the following abbreviations are used throughout the description:

30 CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate
CPG Controlled pore glass

	DCM	Dichloromethane
	DMF	N,N-dimethylformamide
	DMSO	Dimethylsulfoxide
	EDAC	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
5	Et ₃ N	Triethylamine
	Fmoc	(9-Fluorenylmethoxycarbonyloxy)
	HOBt	1-hydroxybenzotriazole
	MalBut	Maleimidobutyramide
	MalCap	Maleimidocaproamide
10	NHS-Adipic	N-hydroxysuccinimidyladipamide
	PEG	Poly(ethyleneglycol)
	TBTU	O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
	TCEP	Tris(2-carboxyethyl)phosphine hydrochloride
15	TFA	Trifluoroacetic acid
	TRIS	Tris(hydroxymethyl)aminomethane
	TSTU	O-(N-succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate

20

Reagents and Equipment

The long-chained amine controlled-pore glass (LCA-CPG) was purchased from CPG Inc, New Jersey, USA. D₆-aminobutyric acid was purchased from CDN Isotopes, Quebec, Canada. Fmoc-Rink-polystyrene and 3-formyl-indolyl- acetomidomethyl polystyrene

25 were purchased from CN Biosciences (UK) Ltd., Nottingham, England. The peptide Ac-Glu-Glu-Val-Val-Ala-Cys-AMC peptide was obtained from Bachem, Merseyside, UK. CombiZorb S-monoamine was purchased from Crawford Scientific, Strathaven. α -cyano-4-hydrocinnamic acid, CHAPS, urea, Ficoll PM70 and PD-10 desalting columns were obtained from Amersham Biosciences, Little Chalfont, England. Tris-(2-carboxyethyl)

30 phosphine, hydrochloride was bought from Molecular Probes, AA Leiden, Netherlands. Sequencing grade trypsin was purchased from Promega, Southampton and Ziptips®

from Millipore (UK) Ltd, Watford. Dimethylformamide, methanol, acetonitrile, dichloromethane and ether were all obtained from BDH, Poole. All other materials were purchased from Sigma-Aldrich Company Ltd., Dorset, England.

- 5 The Sieber linker was prepared according to the procedure published by Albericio *et al* ('Preparation and Applications of Xanthenylamide (XAL) Handles for Solid-Phase Synthesis of C-Terminal Peptide Amides under Particularly Mild Conditions', J. Org. Chem. (1996) 61, 6326-6339).
- 10 The D₀-maleimidobutyric acid and D₆-maleimidobutyric acid were synthesised according to the procedure by Rainer and Grahe ('Method for the preparation of N-(carboxyalkyl)maleimides', R.B. Rainer and G.F. Grahe, EP0847991).

The active substitution level (typical values ranged from 1-10 μ mol) of the Fmoc on the
15 carrier was calculated from the UV/VIS absorption spectra at 278nm. The standard procedure was as follows: 2.0mg of the prepared Fmoc solid support was accurately weighed out and suspended in 1.81g of DMF:piperidine (1:1 w/w) solution. The reaction was allowed to proceed to 45 minutes whereby 100 μ l of the supernatant was transferred to a 1ml volumetric flask and diluted with DMF:piperidine (1:1 w/w) solution. The
20 absorbance was measured at 278nm and the loading calculated from the equation below.
$$[c(\text{mmol/g}) = (\text{Abs (absorbance)} \times 10^4) / 10,417 (\epsilon)]$$

HPLC was performed on a Gilson HPLC equipped with Gilson 234 Autoinjector, 321 pump, 170 diode array detector and FC203B fraction collector. The column used (unless
25 otherwise specified) was a Pharmacia Sephasil ST 4.6/250 C18 reversed phase column. Solvent A was 0.1% trifluoroacetic acid/water, solvent B: 0.1% trifluoroacetic acid 90% acetonitrile/10% water. The gradient employed (unless otherwise stated) was 100% aqueous to 20% aqueous over 30 minutes, then 0% aqueous over five minutes, holding at 0% for 1 minute then increasing to 100% aqueous over the next five minutes.

NMR spectra were performed on the Jeol JNM-LA300 FT NMR system in a suitable deuterated solvent.

Matrix assisted laser desorption ionisation mass spectroscopy (MALDI MS) was performed on a Bruker Biflex III instrument. Typically, 5 μ l of the matrix (α -cyano-4-hydroxycinnamic acid at 10mg/ml in 50:50 ethanol: acetonitrile) was diluted with 5 μ l of the sample and 0.5 μ l spotted onto a MALDI anchor target and a MALDI spectra recorded. The machine was calibrated either with [Glu]fibrinopeptide, apamin and angiotensin II or Bradykinin 1-7, Angiotensin I, angiotensin II, substance P, bombesin and adrenocorticotrophic hormone 1-17.

Solvent from HPLC fractions were removed on a Savant 352 Speed vac concentrator with inline Savant RT490 refrigerated condensation trap and Edwards E2M5 high vacuum pump.

Electrospray MS and MS/MS analysis were performed on a Micromass Q-Tof Ultima API tandem mass spectrometer fitted with a Z-spray nanoflow electrospray ion source. The mass spectrometer was operated in positive ion mode with a source temperature of 80°C, a counter current gas flow rate of 40 L/hr and with a potential of 3500V applied to the standard flow probe. The instrument was calibrated with a multipoint calibration using selected ions from the collision-induced dissociation of Glu-fibrinopeptide-B.

Specific Examples

Synthesis of immobilised reagent

The synthesis of a cleavable linker on a solid support with a maleimide protein reactive group is achieved as shown in Figure 1.

To the CombiZorb S-monoamine solid support (500mg, 750 μ mol/g) was added dichloromethane (10ml) and dimethylformamide (1.5ml). 3-Formyl-indol-1-yl-acetic acid

(0.15g, 0.75mmol), N-hydroxybenzotriazole (0.40g, 3.0mmol), 1,3-diisopropylcarbodiimide (0.38g, 3.0mmol) and N,N-diisopropylethylamine (0.15g, 1.1mmol) were added and the reaction stirred for 3 days. The solid support was washed with water (2 x 10ml), methanol (2 x 10ml), DMF (1 x 10 ml) then 50:50 methanol:water (1 x 10ml) and finally methanol (1 x 10ml) and dried under a stream of air.

To the indole derivatised solid support as above (50mg, indole substitution: 206 μ mol/g, 10.3 μ mol) was added dichloromethane (1ml), 1,3-diaminopropane (188.8 μ mol, 29.1mg) and stirred at room temperature for 10 minutes. Sodium triacetoxyborohydride (188.8 μ mol, 40.02 mg) was then added and the reaction stirred at room temperature for 9 hours.

To maleimidocaproic acid (42.2mg, 200 μ mol.) was added dichloromethane (2ml) and DMF (300 μ l) followed by N-hydroxybenzotriazole (0.108g, 800 μ mol), N,N-diisopropylethylamine (0.103g, 800 μ mol) and 1,3-diisopropylcarbodiimide (0.101g, 125.3 μ l, 800 μ mol) and left at room temperature for 30 minutes. The derivatised indole solid support prepared above (40mg) was then added and the reaction left roller mixing at room temperature (25°C) for 17 hours.

The solid support was washed with water (2 x 2ml), methanol (2 x 2ml), water:methanol 50:50 (3 x 2ml), water (2 x 2ml) and finally methanol (2 x 2ml) and dried under a stream of air.

Synthesis of deuterated chemical capture reagent

The incorporation of deuterium into the linker for simultaneous differential analysis of one or more samples is achieved using the same synthetic route as described above for the 'hydrogen' (i.e. non-labelled) species. The label is incorporated into the linker using the same reductive amination procedure used for incorporating the non-labelled linker. The deuterated linker has been represented in Formula II as the d4-1,3-diaminopropane derivative. There are a number of commercially available alternatives for this linker (CDN Isotopes).

<u>Structure</u>	<u>Chemical name</u>	<u>No of D's</u>
$\text{NH}_2\text{CD}_2\text{CD}_2\text{CD}_2\text{CD}_2\text{NH}_2$	1,4-diamino-d8-diamine	8
$\text{NH}_2\text{CD}_2\text{CH}_2\text{CD}_2\text{NH}_2$	1,3-diaminodiamine-1,1-3,3-d4	4
5 $\text{NH}_2\text{CH}_2\text{CD}_2\text{CH}_2\text{NH}_2$	1,3-propanediamine-2,2-d2	2

Fmoc-Sieber-CPG

The LCA-CPG (500mg, 19.25 μmol), Fmoc-Sieber linker (95mg, 192.5 μmol), diisopropylcarbodiimide (25 μl , 192.5 μmol) and hydroxybenzotriazole (26mg, 192.5 μmol) were mixed together in dichloromethane and the reaction allowed to proceed for 15 hours. The solid support was then successively washed with dimethylformamide (2x 10ml), dichloromethane (2x 10ml) and diethyl ether (2x 5ml) before vacuum drying (Figure 5).

15 Sieber-CPG

The Fmoc-Sieber-CPG (275mg) was suspended in anhydrous dichloromethane (1ml) and acetic anhydride (100 μl , 9.56mmol) and triethylamine (100 μl) were added and the reaction allowed to mix for 1 hour at 25°C. The solid support was then collected by filtration and washed successively with dimethylformamide (2 x 2ml), dichloromethane (2x 4ml) and diethyl ether (2x 2ml) before vacuum drying. The Fmoc group was removed from the resin by addition of 50:50 DMF:piperidine to the solid support for one hour followed by washing with dimethylformamide (2 x 2ml), dichloromethane (2 x 4ml) and diethyl ether (2 x 2ml) before vacuum drying (Figure 5).

25 Maleimidocaproic acid-Sieber-CPG

The Sieber-CPG (100mg, 3.83 μmol (assume a loading of 38.3mol/g)) was suspended in anhydrous dimethylformamide (500 μl) and maleimidocaproic acid (8mg, 38.3 μmol), diisopropylcarbodiimide (6 μl , 38.3 μmol) and hydroxybenzotriazole (6mg, 38.3 μmol) were added and the reaction mixed at 25°C for 16 hours. The solid support was then collected by filtration and washed successively with dimethylformamide (2 x 2ml), dichloromethane (2 x 2ml) and diethyl ether (2 x 2ml) before vacuum drying (Figure 5).

Synthesis of Maleimidocaproamide-Rink-CPG

Maleimidocaproamide-Rink-CPG was synthesised as shown in Figure 6. To the p-[(R,S)-
a-[1-(9H-Fluoren-9-yl)-methoxyformamido]-2,4-dimethoxybenzyl]-phenoxyacetic acid
5 (Fmoc Rink) linker (50mg) was added dichloromethane (1ml), hydroxybenzotriazole
(12.5mg), DMF (70µl) and warmed to dissolve. Diisopropylcarbodiimide (14.5µl) was
then added followed by the LCA-CPG (50mg, 38.3µmol/g) and the mixture roller-mixed
at 25°C for 3 hours. The supernatant was removed *in vacuo* and the resin washed with
dichloromethane (2 x 2ml), methanol:water 50:50 (1 x 2ml) and finally methanol (2 x
10 2ml) and dried in a stream of air (51.1mg). Then dichloromethane (0.8ml) was added
followed by piperidine (200µl) and left for 30 minutes at 25°C. The sample was washed
and dried as above to give a white solid (35mg).

To maleimidocaproic acid (25mg) was added diisopropylcarbodiimide (18.5µl) and
15 dichloromethane (0.5ml) followed by diisopropylethylamine (20µl) and Rink-CPG (total,
as above). The mixture was roller-mixed for 2 hours at 25°C and then washed and dried
as above. To maleimidocaproamide-Rink-CPG (4.5mg) was added sodium carbonate
buffer (pH 8.0, 1ml) followed by laminin fragment 925-933 (0.1mg) and left for 16 hours
at 25°C. The supernatant was removed and the solid support washed with water (500µl).
20 Then 10% TFA in water (50µl) was added, the sample zip tipped after 60 minutes and a
MALDI spectra was recorded.

Synthesis of Maleimidocaproamide-Indole-Aminomethylated polystyrene

To (3-formylindolyl)acetamidomethyl polystyrene solid support (200mg) was added 2,2-
25 dimethoxypropane (400µl) and 1,3-diaminopropane (80µl) followed by methanol (2ml)
and left overnight. Sodium triacetoxyborohydride (0.208g) was added to half of the
sample and the reaction roller mixed at 25°C for 24 hours. The solid support was washed
with methanol (2 x 2ml), water (2 x 2ml), water:methanol (50:50, 2ml), methanol (2 x
2ml) and dried under a stream of air.

30

To maleimidocaproic acid (84.4mg) was added dichloromethane (4ml) and DMF (600µl)
followed by N-hydroxybenzotriazole (0.216g), N,N-diisopropylethylamine (0.206g) and

1,3-diisopropylcarbodiimide (0.202 g) and left at room temperature for 30 minutes. The derivatised indole solid support (as above, 43mg) was added to the activated maleimidocaproic acid (2.3ml) and the reaction left at 25°C for 17 hours. The solid support was washed with water (2 x 2ml), methanol (2 x 2ml), water:methanol 50:50 (3 x 2ml), water (2 x 2ml) and finally methanol (2 x 2ml) and dried under a stream of air.

To the *p*-[(R,S)- α -[1-(9H-Fluoren-9-yl)-methoxyformamido]-2,4-dimethoxybenzyl]-phenoxyacetic acid (Fmoc Rink) linker (50mg) was added dichloromethane (1ml), hydroxybenzotriazole (12.5mg), DMF (70 μ l) and warmed to dissolve.

Diisopropylcarbodiimide (14.5 μ l) was then added followed by the LCA-CPG (50mg, 38.3 μ mol/g) and the mixture roller-mixed at 25°C for 3 hours. The supernatant was removed *in vacuo* and the resin washed with dichloromethane (2 x 2ml), methanol:water 50:50 (1 x 2ml) and finally methanol (2 x 2ml) and dried in a stream of air (51.1mg). Then dichloromethane (0.8ml) was added followed by piperidine (200 μ l) and left for 30 minutes at 25°C. The sample was washed and dried as above to give a white solid (35mg).

Capture of Laminin Fragment 925-933 on Maleimidocaproamide-Rink-CPG

To maleimidocaproic acid (25mg) was added diisopropylcarbodiimide (18.5 μ l) and dichloromethane (0.5ml) followed by diisopropylethylamine (20 μ l) and Rink-CPG (total, as above). The mixture was roller-mixed for 2 hours at 25°C and then washed and dried as above. To maleimidocaproamide-Rink-CPG (4.5mg) was added sodium carbonate buffer (pH 8.0, 1ml) followed by laminin fragment 925-933 (0.1mg) and left for 16 hours at 25°C. The supernatant was removed and the solid support washed with water (500 μ l). Then 10% TFA in water (50 μ l) was added, the sample zip tipped after 60 minutes and a MALDI spectra was recorded. A peak at m/z 1177.4 was observed corresponding to laminin fragment 925-933 plus maleimidocaproamide.

Solid phase synthesis of 6-maleimidocaproamide

To Fmoc-Rink-polystyrene solid support (0.5g, 345 μ mol) was added dimethylformamide (3ml) and piperidine (0.6ml) and left roller mixing at 25°C for 60 minutes. The solid

support was then washed with dimethylformamide (2 x 5ml), dichloromethane (2 x 5ml), methanol (2 x 5ml), then solvent allowed to evaporate under a stream of air.

To 6-maleimidocaproic acid (50mg, 0.23mmol) was added TBTU (76mg, 0.25mmol),
5 dichloromethane (0.5ml) and dimethylformamide (0.5ml). After 30 minutes a further 1ml
dimethylformamide was added. The Rink-polystyrene solid support (as above) was then
added and left roller mixing for 3 hours at 25°C. The solid support was washed with
dichloromethane (2 x 3ml), methanol (1 x 2ml), water (2 x 3ml), methanol:water 50:50 (1
x 3ml), methanol (2 x 3ml) and finally dried under a stream of air. To the
10 maleimidocaproic acid-Rink-polystyrene (7.09mg, 2.4µmoles assuming 50% yield), was
added dichloromethane (638µl) and trifluoroacetic acid (63.8µl) and left at 25°C.

To the maleimidocaproic acid-Rink-CPG solid support was added dichloromethane (2ml)
followed by trifluoroacetic acid (20µl) and left for 20 hours at 25°C. Then 5µl was
15 removed and evaporated and 0.1% trifluoroacetic acid/water added (1000µl) of which
135µl was injected onto a C18 column as above (Figure 6). The solid support was then
filtered from the solution using a glass wool plugged pasteur pipette and a further 5ml of
dichloromethane used to wash the resin. The solvent was evaporated in vacuo to give
6- maleimidocaproamide (4.5mg) and then analysed by NMR δH (300 MHz, CDCl₃) 1.28
20 (2H, dd, CH₂), 1.50-1.66 (4H m 2 x CH₂), 2.17 (2H t J=7.5Hz, CH₂), 3.45 (2H t J=6.9 Hz
CH₂), 5.54 (1H s N-H), 5.79 (1H s N-H), 6.67 (2H s H-C=C-H). The retention time of
the maleimidocaproamide was determined to be 11.60 mins, the same retention time as
observed for acidolytic cleavage of Maleimidocaproamide-Sieber-CPG (Figure 8).

25 Calibration of HPLC Integration vs Mass of Maleimidocaproamide

To maleimidocaproamide (0.54mg, 2.57µmol) was added 0.1% trifluoroacetic acid/water
(5.4ml) and both 10µl and 20µl diluted to 135µl with 0.1% trifluoroacetic acid/water and
analysed by HPLC at 215 nm. An integration of 1.0×10^9 was found to equate to 27.57µg
of maleimidocaproamide (Figure 9).

Cleavage kinetics of Maleimidocaproic acid-Sieber-CPG

To maleimidocaproic acid-Sieber-CPG solid support (5.0mg, 4.1 μ mol/g) was added water (490 μ l) and trifluoroacetic acid (5 μ l) at 26°C. At specific time periods 20 μ l was removed and diluted with water (115 μ l). The solution was then injected onto the HPLC.

- 5 The integration of the maleimidocaproamide peak was calculated at each time point, which was plotted against cleavage time to determine the rate of cleavage (Figure 10).

Chemical Capture of Glyceraldehyde 3-Phosphate Dehydrogenase followed by Proteolysis

- 10 To glyceraldehyde 3-phosphate dehydrogenase (8.6mg, 240nmol) was added 6M urea 0.05M TRIS pH 8.0 (1.72ml) followed by TCEP (2mg/ml in 6M urea 0.05M TRIS pH 8.0, 103.5 μ l) and roller-mixed for 15 minutes at 25°C. Then maleimidocaproic acid-Sieber-CPG (9.8mg, 37.2nmol) was added and roller mixed for five hours at 25°C. The supernatant was removed and the resultant solid support was washed with water (2 x 15 1ml), 6M urea, 0.05M TRIS/ pH 8.0 (2 x 1ml) and finally water (2 x 1ml).

- To the above protein-bound solid support was added trypsin (20 μ g/ml, 25 μ l) and 50mM carbonate pH 8.0 (0.5ml) and roller mixed for 1 hour at 25°C. The solid support was then warmed to 37°C for 20 minutes and then the supernatant discarded. The solid support 20 was washed with methanol (200 μ l) then dichloromethane (200 μ l) and finally 200 μ l of dichloromethane in 1% trifluoroacetic acid was added and left 18 hours. The supernatant was removed and both the supernatant and solid support were allowed to evaporate. 5% trifluoroacetic acid in water (100 μ l) was then added and allowed to react at 25°C for 3 hours. The supernatant was then added to the dried down dichloromethane /trifluoroacetic acid fraction. 25

- A Ziptip® was equilibrated in 0.1% trifluoroacetic acid/water and 10 μ l of the cleaved Sieber-CPG adsorbed onto it, debinding in 50% acetonitrile/50% water with 0.1% trifluoroacetic acid. MALDI MS was performed on the material. As expected, two peaks 30 were observed with m/z ratios of 1709.87 and 2080.18 corresponding to sequence 232-245 plus maleimido caproamide and 232-248 plus maleimido caproamide, respectively.

Proteolysis of Creatine Phosphokinase without Chemical Capture

To creatine phosphokinase (2.0mg, 47nmol) was added 100 mM carbonate buffer pH 8.0 (1.00ml) followed by trypsin (35µg, 20µg/ml) and left roller mixing at 25°C for 16 hours.

5 Then TCEP (2mg/ml, 119µl, 830nmol) was added and the reaction left for a further 30 minutes at 25°C. 20µl was removed and added to 5% trifluoroacetic acid/ water (115µl) and HPLC performed collecting one minute fractions, between 6 and 22 minutes (Figure 11). Each 1ml fraction was evaporated *in vacuo* and dissolved in 5µl of 0.1% trifluoroacetic acid/water and a MALDI MS spectra measured. The following peaks were

10 observed, together with assignments (Table 1).

Table 1: m/z Ratios for Digestion of Creatine Phosphokinase

(I and II represent two polypeptide chains)

Fraction number	Peak number								
	1	2	3	4	5	6	7	8	9
5	914.4	936.4	952.4	986.4 (97-105 II)	1008.5 (97-105 + Na ⁺ II)				
7	759.2 (210-215 I)	983.1 (216-223 I)	1130.2 (139-148 II)	1152.2 (139-148 + Na ⁺ II)					
8	759.1 (210-215 I)	1037.2 (243-251 II)	1130.2 (139-148 II)	1150.3	1193.3 (237-247 I)	1458.3 (139-151 I)	1714.4 (12-25 II)		
9	816.1	907.2 (308-314 II)	950.2 (253-259 + Na ⁺ II)	970.2 (33-40 + Na ⁺ II)	986.2 (97-105 II)	1130.1 (139-148 II)	1530.2 (117-130 II)	2595.6 (108-130 II)	2861.2 (342-366 I)
10	1269.2 (305-314 II)	2861.1 (342-366 I)							
11	1269.3 (305-314 II)	2008.4 (321-341 II)							
13	1507.2 (157-170 II)	1529.2 (157-170 + Na ⁺ II)							
14	1643.1 (224-236 II)	1659.2	1675.1 (224-236 + Na ⁺ II)	2870.6 (267-292 II)	3775.7 (93-130 I)				
15	1643.0 (224-236 II)	1659.1	1675.0	3604.7	3645.5 (178-209 II)				

5 Chemical Capture of Creatine Phosphokinase

To creatine phosphokinase (2.93mg) was added 0.1 M phosphate pH 8.0 (1.47ml) and 0.5ml removed. Trypsin (100 μ l, 0.1mg/ml in 50mM acetic acid) was then added and incubated for 30 minutes at 37°C. Then TCEP (14.7 μ l, 2mg/ml in 0.1 M phosphate pH 8.0) was added and left at 37°C for a further 2 hours. 93 μ l of this solution was removed and added to MalBut-Sieber-CPG (5.72mg) and left for 90 minutes at 25°C. The supernatant was removed and water (500 μ l) added to the solid support, mixed by multiple

inversion and then the supernatant discarded. A solution of 8M urea, 4% CHAPS, 40mM Tris pH 8.0 (500 μ l) was added and roller mixed for 10 minutes before discarding the supernatant. Then water (500 μ l) was added, mixed by multiple inversion and the supernatant discarded, followed by addition of 0.1-M phosphate pH 8.0, 3 M sodium chloride (500 μ l) and roller mixed for 60 minutes. The solid support was washed twice more with water (500 μ l); mixing by multiple inversion and the supernatant discarded. Finally 1% trifluoroacetic acid in water (50 μ l) was added and left overnight (16 hours) at room temperature (25°C) and a MALDI spectrum recorded (Figure 12).

10 Maleimidobutyric acid-Sieber-CPG (X D₀-MalBut, Y D₆MalBut)

The Sieber-CPG (100mg, 3.83 μ mol) was suspended in anhydrous dimethylformamide (500 μ l) and the D₀- or D₆-maleimidobutyric acid (7mg, 38.3 μ mol), diisopropylcarbodiimide (6 μ l, 38.3 μ mol) and hydroxybenzotriazole (6mg, 38.3 μ mol) were added and the reaction mixed at 25°C for 16 hours. The resin was then collected by filtration and washed successively with dimethylformamide (2 x 2ml), dichloromethane (2 x 2ml) and diethyl ether (2 x 2ml) before vacuum drying.

Cleavage reactions

In a typical test cleavage reaction, 2mg of the prepared Mal-Sieber-CPG resin was accurately weighed into an Eppendorf tube and 5% aq. TFA added. The reaction was mixed for 2 hours and then 20 μ l removed and diluted to 135 μ l with 0.1% aqueous TFA and an HPLC performed. The desired cleavage product was found to have a retention time of 8.0 \pm 0.2 minutes. The loading on the resin was then calculated from the area under the peak compared to known quantities of D₆ or D₀-maleimidobutyric acid standard from a dilution series.

Relative Cleavage Kinetics D₀ and D₆ Maleimidobutyric acid-Sieber-CPG

To the D₀ or D₆ MalBut-Sieber-CPG solid support (N mg) was added 1% trifluoroacetic acid in water (N x 100 μ l) at 25°C. At specific time periods 20 μ l was removed and diluted with water (115 μ l) and injected onto the HPLC. The integration of the

maleimidobutyramide at 8 mins was calculated in order to establish the kinetics of the reaction (Figure 13).

Determination of the substitution of maleimidobutyric acid from the area under the HPLC peak

A series of dilutions of the D₀-maleimidobutyric acid and D₆-maleimidobutyric acid were performed to determine the loading of the resin after the cleavage reaction. Thus it was calculated that an area of 6.69×10^6 equates to 1×10^{-9} moles of maleimidobutyric acid at 215 nm (Figure 14).

Chemical Capture of Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH) on Maleimidobutyric acid-Sieber-CPG Solid Support

To GAPDH (1.33mg, 37nmol) was added lysis buffer (0.577ml; 8M urea, 4% CHAPS (w/v), 40mM tris pH 8.0) followed by TCEP (10mM, 61μl, 610nmol) and incubated for 35 minutes at 37°C. MalBut-Sieber-CPG (17.8mg) was added to the above reduced protein solution (55.3μl) and left for 30 minutes at 37°C. The solid support was then washed with water (5 x 500μl). Then N-acetyl cysteine (2mg/ml in 0.1 M carbonate pH 8.0, 104.5μl, 1.28μmol) was added and left for 15 mins at 25°C. The solid support was washed with water (3 x 500μl). 5.8μl trypsin at 20μg/ml in 0.1 M carbonate pH 8.0 was added to above solid support followed by 94.2μl of 0.1M carbonate pH 8.0 and left at 25°C for 16 hours. The solid support was then washed with water (4 x 500μl), methanol:water 50:50 (2 x 500μl), methanol (2 x 500μl) and finally water (3 x 500μl). 1% trifluoroacetic acid in water (100μl) at 25°C was then added and a MALDI MS recorded after 2 hours (figure 6). MS-MS analysis was performed by dilution of the peptide to a concentration of approximately 100 fmol/μl followed by direct infusion into the mass spectrometer at a flow rate of 250nl/min (Figure 15).

The peptide was shown to have the amino acid sequence:

Val-Pro-Thr-Pro-Asn-Val-Ser-Val-Val-Asp-Leu-Thr-Cys(MalBut)-Arg

corresponding to sequence 232-245 of rabbit GARDH. The experimental results are in complete agreement with those in the literature for this sequence (VPTPNVSVVDLTCR; SwissProt accession number: P46406).

5 One pot tryptic digestion and capture of Glyceraldehyde 3-phosphate Dehydrogenase on Maleimidobutyric acid -Sieber-CPG

To GAPDH (1.15mg) was added 0.1 M tris pH 8.0 (200 μ l) followed by trypsin (40 μ g/ml, 0.15ml) together with H₆ MalBut-Sieber-CPG (5.0mg) and TCEP (1mg/ml in water, 23.5 μ l). The reaction was left roller mixing at 25°C for 16 hours then washed twice with
10 water (1.5ml), once with methanol:water 50:50 (1.5ml), once with methanol (1.5ml) and finally twice with water (1.5ml). 1% TFA/water (100 μ l) was then added and left for 2 hours at room temperature. A MALDI spectra was recorded. Peaks at m/z 1681.9 and m/z 2052.2 were observed, corresponding to sequence 232-245 plus MalBut and 232-248 plus MalBut, together with an extra peak at m/z 1763.9 and 1828.2, the former being 307-320,
15 the latter being unidentified.

Kinetics of capture of laminin fragment 925-933 on Maleimidobutyric acid -Sieber-CPG

To the laminin fragment 925-933 in 0.1 M phosphate pH 8.0 (1 mg/ml, 50 μ l) was added TCEP (2mg/ml in water, 7.4 μ l) and left for 60 minutes at 25°C. Then D₆ MalBut-Sieber-
20 CPG (5.85mg) was added to 29.5 μ l of the above solution. At 60 minutes, 2 μ l was removed and analysed by HPLC. No trace of the peptide fragment was observed.

Differential Analysis of Peptides on a D₀ and D₆ Maleimidobutyric acid-Sieber-CPG Solid Support

25 Three times 5.0mg of the H₆ linker (5.87nmol) were weighed out into 0.5ml Eppendorf tubes together with the same weight of the D₆ linker into three separate tubes (3.1nmol). Reduced laminin fragment 925-933 (0.2mg/ml in 0.1M phosphate pH 8.0, 207nmol) was added to the H₆ and D₆ linkers as follows:

Solid support	Volume 0.2mg/ml laminin fragment/ μ l	Volume 0.2mg/ml laminin fragment/ μ l	Volume 0.2mg/ml laminin fragment/ μ l
H ₆ MalBut-Sieber-CPG	1.9 (1)	7.5 (2)	7.5 (3)
D ₆ MalBut-Sieber-CPG	7.5 (4)	7.5 (5)	1.9 (6)

Bold = tube number

The total volume was then made up to 20 μ l in all cases with 0.1M phosphate pH 8.0. The reactions were left at 25°C for two hours with occasional agitation, then the supernatant removed. 400 μ l of water was then added to the D₆ solid supports and the solid support transferred to the corresponding vial (4 to 1, 5 to 2 and 6 to 3). The particles were then thoroughly mixed by repeated agitation and the supernatant removed after centrifugation. 1% trifluoroacetic acid in water (100 μ l) was then added to each of the three vials and left at 25°C for 2 hours. A MALDI MS was recorded on the cleavage solution and the relative integrations of the laminin plus maleimidobutyramide peaks at *m/z* ratios of 1149 and 1155 were measured for each of the three (Figures 16-18). The measured relative integrations were 1:3.92, 1:1.03 and 1:0.24 compared with the expected values of 1:3.94, 1:1 and 1:0.25. As can be seen from Figure 19 the theoretical and measured values overlay each other.

Lysine reactive solid support synthesis

The Fmoc group was removed from Fmoc-Sieber-CPG (60mg, 2.30 μ mol (assumed loading 38.3 μ mol/g)) by addition of 50:50 DMF:piperidine (500 μ l) to the solid support for one hour followed by washing with dimethylformamide (2 x 2ml), dichloromethane (2 x 2ml) and diethyl ether (2 x 1ml) before vacuum drying.

The Sieber-CPG (50mg, 1.92mol) was suspended in anhydrous dimethylformamide (500 μ l) and hexanedioic acid (7mg, 38.3 μ mol), diisopropylcarbodiimide (4 μ l, 19.2 μ mol) and hydroxybenzotriazole (4mg, 19.2 μ mol) were added and the reaction mixed at 25°C for 16 hours. The resin was then collected by filtration and washed successively with

dimethylformamide (2 x 2ml), dichloromethane (2 x 2ml) and diethyl ether (2 x 1ml) before vacuum drying.

5 The resin was resuspended in anhydrous DMF (1ml) and TSTU (5mg, 19.2 μ mol) and triethylamine (4 μ l, 19.2 μ mol) were added and the reaction mixed for 16 hours. The resin was then collected by filtration and washed successively with dimethylformamide (2 x 2ml), dichloromethane (2 x 2ml) and diethyl ether (2 x 1ml) before vacuum drying.

Chemical Capture of γ -amino Group Functionality on NHS-Adipic acid-Sieber-CPG

10 [Val-OH]- α -melanocyte stimulating hormone (1mg/ml in 0.1M phosphate pH 8.0, 20.5 μ l, 12.3nmol) was added to NHS-Adipic-Sieber-CPG (2.47mg, 12.3 μ mol assuming substitution = 5 μ mol/g) and left for 60 minutes at 25°C. The solid support was washed with water (3 x 500 μ l). Trifluoroacetic acid (1% in water, 100 μ l) was added to the solid and left at 25°C for 1 hour and a MALDI spectrum then recorded (Figure 20). As
15 exepcted, major peaks at m/z ratios of 1665.78 and 1792.81 were observed corresponding to the unlabelled and labelled peptide, respectively.

Chemical Capture of α -amino Group Functionality on NHS-Adipic acid-Sieber-CPG

To bag cell peptide 1-8 (10.6 μ l, 1mg/ml in water, 10.5nmol) was added 0.1M phosphate
20 pH 8.0 (31.8 μ l) and NHS-Adipic-Sieber-CPG (2.10mg, 10.5nmol assuming substitution = 5 μ mol/g) and left at 25°C for 65 minutes. The solid support was washed with water (3 x 500 μ l), 1% trifluoroacetic acid in water (100 μ l) added and left at 25°C for 60 minutes and then a MALDI spectrum recorded (Figure 21). Major peaks at m/z ratios of 1009.65 (unlabelled peptide) and 1136.73 (labelled peptide) were observed, as expected.

25

Chemical Capture of Hydrophobic Peptides on Maleimidobutyric acid-Sieber-CPG

The potential for capture of hydrophobic peptides in organic solvents was investigated in dimethylsulphoxide and dimethylformamide:

30

(i) *Dimethylformamide*

To Ac-Glu-Glu-Val-Val-Ala-Cys-AMC (0.364mg, 429nmol) was added dimethylformamide (530 μ l) and the peptide dissolved by heating to around 60°C. 15 μ l of this solution was added to MalBut-Sieber-CPG (4.36 mg, 12.1nmol) and left at 25°C for 2 hours. The solid support was then washed twice with methanol (500 μ l), and 1% TFA in methanol added (50 μ l). The reaction was left overnight, then a MALDI spectrum recorded.

(ii) *Dimethylsulphoxide*

To Ac-Glu-Glu-Val-Val-Ala-Cys-AMC (0.14mg, 165nmol) was added dimethylsulphoxide (205 μ l) and dissolved by heating to around 60°C. 18.5 μ l of this solution was added to MalBut-Sieber-CPG (5.4mg, 15.0nmol) and left at 25°C for 2 hours. The solid support was then washed once with dimethylsulphoxide (200 μ l), once with methanol (500 μ l) discarding the supernatant without roller mixing, then twice with methanol (500 μ l), the methanol discarded and 1% TFA in methanol added (50 μ l). The reaction was left overnight, then a MALDI spectrum recorded.

A peak at a m/z ratio of 1052.5 was observed in both cases corresponding to the expected Ac-Glu-Glu-Val-Val-Ala-Cys-AMC plus maleimidobutyramide.

Quantitative capture of reduced and denatured protein on Maleimidobutyric acid -Sieber-CPG Solid Support followed by proteolysis and cleavage

To GAPDH (2.78mg) was added lysis buffer (625 μ l; 8M urea 4% CHAPS (w/v), 40 m phosphate pH 8.0) and TCEP (33 μ l, 2mg/ml in lysis buffer) and heated to 100°C for 2 minute, then cooled rapidly under a stream of cold water. The volumes specified below were added to the H₆ and D₆ MalBut-Sieber-CPG solid supports and the mixture left roller mixing at 26°C for 4 hours.

Expt ID	Mass solid support/ mg	Identity solid support	Volume GAPDH/ μ l	Volume lysis buffer/ μ l
1	5.15	H ₆	4	17
2	5.45	H ₆	16	5
3	5.23	D ₆	16	5
4	5.76	D ₆	4	17

Tube 1 was then transferred to tube 3, tube 2 transferred to 4 and each reaction washed twice with water (500 μ l), roller mixing for 2 minutes then decanting off the supernatant. N-acetyl cysteine (10.4 μ l, 10 mg/ml in 0.1 M phosphate pH 8.0) was added together with
 5 0.1 M phosphate pH 8.0 (10 μ l) and roller mixed at 26°C for 10 minutes. The solid support was then washed with water (2 x 500 μ l), roller mixing for 2 minutes prior to decanting the supernatant. Trypsin (40 μ l, 100 μ g/ml in 50 mM acetic acid) was added to each together with 0.1 M phosphate pH 8.0 (40 μ l) and roller mixed at 26°C for 30 minutes, then incubated at 37°C in a water bath for 16 hours. The solid supports were
 10 washed with water (2 x 500 μ l) and 8M urea, 4% (w/v) CHAPS, 40mM phosphate pH 8.0 (500 μ l) was added and roller mixed at 26°C for 50 minutes. The solid support was washed once with water (500 μ l) and then 0.1 M phosphate pH 8.0 3M sodium chloride (500 μ l) was added and roller mixed for a further 50 minutes at 26°C. The solid support was washed a further two times with water (500 μ l), roller mixing for 2 minutes in
 15 between. Then 1% TFA in water (50 μ l) was added to each vial and left for 3 hours at 25°C roller mixing and a MALDI spectra recorded of the supernatant. The relative integrations of the H₆:D₆ peak at m/z 1681 and m/z 1687 were 1:3.02 and 1:0.21 compared to the theoretical value of 1:4 and 1:0.25.

20 Synthesis of MalBUT-Sieber-Ficoll

To a solution of the Fmoc-Sieber linker (10mg, 0.06mmol) in anhydrous DMSO (500 μ l) was added TSTU (17mg, 0.12mmol) and diisopropylethylamine (8 μ l, 0.12mmol) and the reaction mixed for 30 minutes. To this solution was added Ficoll PM70 (Amersham Biosciences) (25mg) and diisopropylethylamine (8 μ l, 0.12mmol) and the mixture

agitated. After 2 hours the solution was treated with piperidine (100 μ l) to cause removal of the Fmoc protecting group. The solution was diluted to 2.5ml with deionised water and purified on a Pharmacia PD-10 desalting column. The desired fraction was collected and the water removed *in vacuo* to afford a white solid of Sieber-Ficoll.

- 5 To a solution of maleimidobutyric acid (24mg, 0.06mmol) in anhydrous DMSO (500 μ l) was added TSTU (17mg, 0.12mmol) and diisopropylethylamine (8 μ l, 0.12mmol). After stirring for 30 minutes the Sieber-Ficoll (see above) and diisopropylethylamine (8 μ l, 0.12mmol) were added and the solution stirred for 2 hours. The solution was diluted to 2.5ml with deionised water and purified on a Pharmacia PD-10 desalting column.

10

Cleavage reaction

To MalBut-Sieber-Ficoll (475 μ l) was added TFA (25 μ l) and left at 26°C for 16 hours.

135 μ l was injected onto an HPLC, giving a peak at 8.3mins believed to be

maleimidobutyramide. To confirm the presence of the amide, authentic material was

- 15 produced by addition of MalBut-Sieber-CPG (3.81mg) to 1%TFA in water (381 μ l) and the reaction left for 30 minutes at 26°C. An equimass amount of the cleaved authentic material was mixed with the cleaved MalBut-Sieber-Ficoll solution and the two co-injected onto the HPLC. The putative maleimidobutyramide from acidolytic cleavage of MalBut-Sieber-Ficoll appeared at identical retention time to authentic material.

20

The Chemical Capture and cleavage from MalBut-Sieber-Ficoll was demonstrated as follows: to MalBut-Sieber-Ficoll (475 μ l) was added laminin fragment 925-933 (1mg/ml in 0.1M phosphate pH 8.0, 50 μ l) and left at 26°C for 20 minutes. The Ficoll was then desalted on a Pharmacia PD-10 column into water, taking 1 minute fractions. 10 μ l TFA
25 was added to each fraction and left for 16 hours at 26°C. A MALDI spectra was recorded on each fraction. A peak at 1149.27, corresponding to laminin fragment 925-933 plus maleimidobutyramide, was observed.

Protein extraction from *Escherichia coli*

- 30 Protein extraction from the control and stressed population is achieved following cell lysis. 50ml of *Escherichia coli* cells from an overnight culture of each sample is

harvested by centrifugation and the supernatant discarded. The cell pellet produced is dissolved in lysis buffer (10mM tris pH 8.0, 5 mM magnesium acetate, 8 M urea, 4% CHAPS) and incubated at 4 °C for 1 hour. The lysate is sonicated until the solution becomes clear. The final concentration of protein can be determined using a BCA protein assay (BioRad).

Protein reduction and trypsin digestion

The lysate is reduced by addition of 30µl of 10 mM tris(2-carboxyethyl)phosphine hydrochloride to 300µl of each cell lysate and incubated for 30 minutes at 37°C. Both cell lysates are then diluted 1:1 with 100mM bicarbonate buffer pH 8.0, 0.5ml total volume to give a protein solution of around 2.5mg/ml.

Trypsin (100µg/ml in 1mM hydrochloric acid, 0.1% (w/v), 12.5µl) is added to each of the cell lysates above and left at 25°C for 20 hours. The reaction is quenched by the addition of 2 µl of 0.1 mg/ml Nα-tosyl-L-lysyl chloromethyl ketone (TLCK) as a trypsin inhibitor.

Labelling of tryptic digest

Each of the reduced and digested protein lysates (500 µl as above) is added to the solid support synthesised as described above (0.1 g) containing either the deuterium or the proton label at pH 8.0 and the reaction is incubated at 25°C for 2 hours. The two labelling reactions / resins are then pooled in a single tube for further processing. The excess maleimide functionalities on the resin are quenched by the addition of 0.16g of 2-mercaptoethanol and incubated at 25°C for 15 minutes. The resin is washed thoroughly with 0.1 M phosphate pH 7.0 (10ml) to remove unbound peptides and mercaptoethanol.

Cleavage of labelled peptides from resin and separation

The labelled peptides are cleaved from the resin by the addition of 5ml of 1% trifluoroacetic acid in to the pooled resin-bound peptides and incubated at 25°C for 60 minutes. The supernatant is collected and the resultant peptide mixture injected onto a peptide C₁₈ column pre-equilibrated in 0.1% trifluoroacetic acid/water. The peptides are

separated using an increasing gradient of 90% acetonitrile/10% water with 0.1% trifluoroacetic acid over 60 minutes separation run. 1 min (1ml) fractions are collected.

MS analysis of peptide fractions

- 5 The peptide fractions are dissolved in 5 μ l of 0.1% trifluoroacetic acid in water followed by the addition of 5 μ l of 10mg/ml α -cyano-4-hydrocinnamic acid in 50:50 acetonitrile:ethanol. The peptide-matrix sample (0.5 μ l) is spotted onto a MALDI target plate and the molecular weight of the peptide measured in positive ion reflectron mode. The relative integration of all peaks shifted by 4 Da is determined for relative
- 10 quantification of the component peptides.
-

CLAIMS

1. A capture reagent having Formula (I):

5 PRG-L-X-carrier
(I)

wherein:

PRG is a peptide or protein reactive group
L is a linker group
10 X is a cleavable group

2. A capture reagent as claimed in claim 1, wherein the peptide or protein reactive group PRG is selected from the group consisting of maleimide, N-hydroxysuccinimidyl ester, pyridyldisulfide, vinylsulfone, iodoacetamide, epoxide, nitrile, aryl thiol, sulfonated
15 alkyl, isothiocyanate, isocyanate, imidoester, sulphonyl halide, aldehyde, ketone, amine, alcohol, hydrazine, fluorophosphonate, α -halo methyl ketone, acyloxymethyl ketone and 4-(phenylamino)quinazoline.

3. A capture reagent as claimed in either of claims 1 or 2, wherein the peptide or
20 protein reactive group PRG is maleimide.

4. A capture reagent as claimed in either of claims 1 or 2, wherein the peptide or protein reactive group PRG is N-hydroxysuccinimidyl ester.

- 25 5. A capture reagent as claimed in any of claims 1 to 4, wherein the linker L group is selected from the group consisting of ether, polyether, amide, polyamide, polythioether, disulfide, silyl ether, alkyl, alkenyl, aryl, diaryl and alkyl-aryl group.

6. A capture reagent as claimed in claim 5, wherein said linker group L is a C₆ or a
30 C₄ alkyl group.

7. A capture reagent as claimed in any of claims 1 to 6, wherein the linker group L comprises a detectable label moiety characterised in that cleavage of the cleavable group results in the detectable label moiety remaining bound to the PRG.

5 8. A capture reagent as claimed in claim 7, wherein said detectable label moiety is selected from a stable isotopic label, a radioisotopic label, a chromophore or a fluorophore.

9. A capture reagent as claimed in claim 8, wherein said isotopic label is selected
10 from the group consisting of ^2H , ^{13}C , ^{15}N , ^{17}O , ^{18}O , ^{34}S , ^{33}S and ^{36}S .

10. A capture reagent as claimed in claim 8, wherein said fluorophore is a fluorescent dye selected from the group consisting of fluorescein, rhodamine, coumarin, cyanine dye (CyDyesTM), BODIPYTM dye and squarate dye.

15

11. A capture reagent as claimed in any of claims 1 to 10, wherein said cleavable group X is cleavable by treatment with an agent selected from the group selected from acid, base and enzyme.

20

12. A capture reagent as claimed in any of claims 1 to 10, wherein the cleavable group X is cleavable by means selected from the group consisting of photochemical, thermal, electrochemical, reductive, nucleophilic and electrophilic cleavage.

25

13. A capture reagent as claimed in claim 11, wherein the acid cleavable group X is selected from the group consisting of 3-(aminomethyl)-indol-1-yl-acetic acid, 9(amino-xanthen-3-yl)oxy acetic acid and 4-[amino-(2,4-dimethoxyphenyl)-methyl]-phenol.


14. A capture reagent as claimed in any of claims 1 to 13 wherein the carrier is a solid support.

30

15. A capture reagent as claimed in any of claims 1 to 13, wherein the carrier is a water soluble carrier.

16. A capture reagent as claimed in claim 15, wherein said water soluble carrier
5 comprises Ficoll PM70.


17. A capture reagent of Formula (II):



Formula (II)

10


18. A capture reagent of Formula (III)



Formula (III)

15

19. A capture reagent of Formula (IV)



Formula (IV)

20. A method for making a capture reagent as claimed in any of claims 1 to 19.
21. A method for selective labelling and purification of proteins and peptides comprising the steps of
- a) providing a capture reagent as claimed in any of claims 1 to 19 to a sample containing proteins or peptides under conditions to promote attachment of the proteins or peptides to the PRG;
 - b) releasing captured components from the carrier; and
 - c) detecting and identifying the released components.
22. A method for selective labelling and purification of proteins and peptides in one or more samples containing mixtures of proteins or peptides comprising:
- a) providing a capture reagent as claimed in any of claims 1 to 19 to one or more samples containing proteins or peptides under conditions to promote attachment of the proteins or peptides to the PRG, wherein the detectable label of the capture reagent provided to one sample is distinguishable from that provided to another;
 - b) releasing captured components from the carrier; and
 - c) detecting and identifying the released components.

23. The method of claim 21 or 22, further comprising a pre-treatment step wherein functional groups on the protein or peptide are modified to render them reactive with the protein reactive group PRG prior to conducting step a).

5 24. The method of claim 23, wherein modification comprises treatment of carboxylic acid groups on the peptide or protein with carbodiimide.

25. The method of claim 23, wherein modification comprises elimination of phosphate groups on the peptide or protein to leave a reactive alkene group which,
10 optionally, may be converted to a thiol group.

26. The method of claim 23, wherein modification comprises oxidation of vicinal diol groups or dehydration and reduction of aldehyde or ketone groups in carbohydrate-containing peptides and proteins.

15

27. The method as claimed in any of claims 22 to 26 further comprising:
d) measuring the relative abundance of the released components derived from each sample.

20 28. The method as claimed in any of claims 22 to 27 wherein the captured samples are mixed prior to releasing the captured components from the carrier.

29. The method as claimed in any of claims 22 to 28 further comprising a washing step prior to step b).

25


30. A use of a capture reagent as claimed in any of claims 1 to 19 in analysis of proteomes from one or more different samples.

31. A kit for use in the analysis of proteomes, said kit comprising a capture reagent as
30 claimed in any of claims 1 to 19.

32. An automated system for analysis of proteomes comprising use of a capture reagent as claimed in any of claims 1 to 19.


1/16

Fig.1.




2/16

Fig.2.




3/16

Fig.3.




4/16

Fig.4.



5/16

Fig.5.



i) Hydroxybenzotriazole, diisopropylcarbodiimide, dichloromethane, LCA-CPG


ii) 50% piperidine in dimethylformamide (v/v)

iii) Acetic anhydride, triethylamine, dichloromethane

iv) Maleimidobutyric acid, diisopropylcarbodiimide, hydroxybenzotriazole, dimethylformamide

6/16


Fig.6.

i) Hydroxybenzotriazole, diisopropylcarbodiimide, CPG-NH₂ in DCM/DMF

ii) Piperidine, DCM

iii) Maleimidocaproic acid, diisopropylcarbodiimide, diisopropylethylamine, DCM

Fig.7.



i) 2,2-dimethoxypropane, 1,3-diaminopropane, methanol
 ii) Maleimidocaproic acid, N-hydroxybenzotriazole, N,N-diisopropylethylamine, 1,3-diisopropylcarbodiimide, DCM, DMF

7/16

Fig.8.





Fig.9.



8/16

Fig.10.






Fig.11.

Chromatogram



9/16

Fig.12.



10/16

Fig.13.






Fig.14.

Dilution series to show the correlation between quantity of compound and area under the curve




11/16

Fig.15.




12/16

Fig.16.




13/16

Fig.17.



14/16

Fig.18.



15/16

Fig.19.






Fig.20.



16/16

Fig.21.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 January 2003 (16.01.2003)

PCT

(10) International Publication Number
WO 03/005026 A3

(51) International Patent Classification⁷: G01N 33/68,
C07K 1/13, 1/14, A61K 47/48

(74) Agents: HAMMER, Catriona, MacLeod et al.;
Amersham Plc, Amersham Place, Little Chalfont, Buck-
inghamshire HP7 9NA (GB).

(21) International Application Number: PCT/GB02/03035

(22) International Filing Date: 1 July 2002 (01.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0116143.9 2 July 2001 (02.07.2001) GB

(71) Applicant (*for all designated States except US*): AMER-
SHAM BIOSCIENCES UK LIMITED [GB/GB]; Amer-
sham Place, Little Chalfont, Buckinghamshire HP7 9LL
(GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): OSBORN, Nigel,
John [GB/GB]; Amersham Biosciences UK Limited, The
Grove Centre, White Lion Road, Amersham, Bucking-
hamshire HP7 9LL (GB). WILLIAMS, Karen [GB/GB];
Amersham Biosciences UK Limited, The Grove Centre,
White Lion Road, Amersham, Buckinghamshire HP7
9LL (GB). SWEET, Alison, Claire [GB/GB]; Amersham
Biosciences UK Ltd, The Grove Centre, White Lion Road,
Amersham, Buckinghamshire HP7 9LL (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
26 June 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: CHEMICAL CAPTURE REAGENT

(57) Abstract: Disclosed is a capture reagent having Formula (I): PRG-L-X-carrier wherein: PRG is a peptide or protein reactive group L is a linker group X is a cleavable group. Also disclosed is a method for selective labelling and purification of proteins and peptides comprising using a capture reagent of Formula (I).



WO 03/005026 A3

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/GB 02/03035

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/68 C07K1/13 C07K1/14 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 495 265 A (AKZO NV) 22 July 1992 (1992-07-22) page 10, line 25; claim 1 ---	1-3, 5, 11, 12, 14, 15, 20
X	WO 99 34833 A (SHEARWATER POLYMERS INC ; ZHAO XUAN (US); HARRIS J MILTON (US)) 15 July 1999 (1999-07-15) the whole document ---	1-6, 11, 12, 14, 15, 20
X	US 6 130 094 A (MUJUMDAR RATNAKAR B ET AL) 10 October 2000 (2000-10-10) column 2, line 39 - column 4, line 45 column 8, line 15 - line 36 table 1 --- -/-	1-8, 10-12, 14, 15, 20-22, 30, 31



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

13 January 2003

Date of mailing of the international search report

28.03.03

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Döpfer, K-P

INTERNATIONAL SEARCH REPORT

Int'l Application No.
PCT/GB 02/03035

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 03106 A (SHEARWATER POLYMERS INC ;HARRIS J MILTON (US); KOZLOWSKI ANTONI (U) 30 January 1997 (1997-01-30) the whole document	1-6,11, 12,14, 15,20
X	US 5 889 155 A (ASHKENAZI AVI J ET AL), 30 March 1999 (1999-03-30) the whole document	1-8, 10-12, 14,15, 20-22, 30,31
X	US 5 521 290 A (MORGAN JR A CHARLES ET AL) 28 May 1996 (1996-05-28) the whole document	1-8, 10-12, 14,15, 20-22, 30,31
X	US 5 741 686 A (COOLIDGE THOMAS R ET AL) 21 April 1998 (1998-04-21) the whole document	1-8, 10-12, 14,15, 20-22, 30,31
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US1986 HULTIN T: "A CLASS OF CLEAVABLE HETEROBIFUNCTIONAL REAGENTS FOR THIOL-DIRECTED HIGH-EFFICIENCY PROTEIN CROSSLINKING SYNTHESIS AND APPLICATION TO THE ANALYSIS OF PROTEIN CONTACT SITES IN MAMMALIAN RIBOSOMES" Database accession no. PREV198682050500 XP002227046 abstract & ANALYTICAL BIOCHEMISTRY, vol. 155, no. 2, 1986, pages 263-269, ISSN: 0003-2697	1-8, 10-12, 14,15, 20-22, 30,31

INTERNATIONAL SEARCH REPORT

national application No.
PCT/GB 02/03035

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-31(all partially)

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-31 (all partially)

Capture reagents wherein the PRG is reactive to amino, thiol or hydroxy groups, linked (labelled) via a cleavable moiety to a carrier, methods using these capture reagents and kits comprising these capturing reagents

1.1. Claims: 1-6,11-20

Capture reagents wherein the PRG is reactive to amino, thiol or hydroxy groups, linked (unlabelled) via a cleavable moiety to a carrier

2. Claims: 1,2,5-16,20-31 (all partially)

Capture reagents wherein the PRG is reactive to carboxylic acid functionalities, linked (labelled) via a cleavable moiety to a carrier, methods using these capture reagents and kits comprising these capturing reagents

3. Claims: 1,2,5,6,11-16,20 (all partially)

Capture reagents wherein the PRG is reactive to carboxylic acid functionalities, linked (unlabelled) via a cleavable moiety to a carrier, methods using these capture reagents and kits comprising these capturing reagents

4. Claims: 1,2,5-16,20-31 (all partially)

Capture reagents wherein the PRG is reactive to phosphoric/phosphonic acid functionalities, linked (labelled) via a cleavable moiety to a carrier, methods using these capture reagents and kits comprising these capturing reagents

5. Claims: 1,2,5,6,11-16,20 (all partially)

Capture reagents wherein the PRG is reactive to phosphoric/phosphonic acid functionalities, linked (unlabelled) via a cleavable moiety to a carrier, methods using these capture reagents and kits comprising these capturing reagents

6. Claims: 1,2,5-16,20-31 (all partially)

Capture reagents wherein the PRG is reactive to carbohydrate functionalities, linked (labelled) via a cleavable moiety to a carrier, methods using these capture reagents and kits comprising these capturing reagents

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. Claims: 1,2,5,6,11-16,20 (all partially)

Capture reagents wherein the PRG is reactive to carbohydrate functionalities, linked (unlabelled) via a cleavable moiety to a carrier, methods using these capture reagents and kits comprising these capturing reagents

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1 and claims dependent thereon relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds wherein PRG is in particular maleimidyl linked (either with or without label) via a cleavable linkage to any carrier (to be interpreted in the broadest sense).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/GB 02/03035

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0495265 A	22-07-1992	AT 109476 T AU 646121 B AU 9009891 A CA 2058595 A DE 69103255 D DE 69103255 T DK 495265 T ES 2061166 T FI 916131 A HU 60484 A IE 914567 A JP 4334377 A NO 920040 A,B NZ 241217 A PT 99954 A,B US 5306809 A ZA 9110203 A	15-08-1994 10-02-1994 28-01-1993 01-07-1992 08-09-1994 08-12-1994 02-01-1995 01-12-1994 01-07-1992 28-09-1992 01-07-1992 20-11-1992 01-07-1992 23-12-1993 30-06-1993 26-04-1994 27-01-1993
WO 9934833 A	15-07-1999	AU 755051 B AU 2221499 A CA 2316834 A EP 1053019 A US 6362276 B US 2001016624 A	05-12-2002 26-07-1999 15-07-1999 22-11-2000 26-03-2002 23-08-2001
US 6130094 A	10-10-2000	US 6008373 A AT 210292 T CA 2178308 A DE 69617531 D DE 69617531 T EP 0747700 A EP 0943918 A ES 2170204 T GB 2301833 A,B JP 2843296 B JP 9104825 A US 6479303 B	28-12-1999 15-12-2001 08-12-1996 17-01-2002 08-08-2002 11-12-1996 22-09-1999 01-08-2002 18-12-1996 06-01-1999 22-04-1997 12-11-2002
WO 9703106 A	30-01-1997	US 5672662 A AU 6345796 A	30-09-1997 10-02-1997
US 5889155 A	30-03-1999	US 5329028 A US 6124435 A US 5929211 A US 5605791 A	12-07-1994 26-09-2000 27-07-1999 25-02-1997
US 5521290 A	28-05-1996	US 5066789 A CA 2000039 A DE 68924783 D DE 68924783 T EP 0434765 A JP 4504248 T WO 9003401 A US 5633351 A	19-11-1991 31-03-1990 14-12-1995 28-03-1996 03-07-1991 30-07-1992 05-04-1990 27-05-1997
US 5741686 A	21-04-1998	US 5279954 A AT 175426 T AU 646638 B	18-01-1994 15-01-1999 03-03-1994

INTERNATIONAL SEARCH REPORT

information on patent family members

Inte onal Application No

PCT/GB 02/03035

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5741686 A		AU 6030090 A	17-01-1991
		CA 2063434 A	31-12-1990
		DE 69032883 D	18-02-1999
		DE 69032883 T	19-08-1999
		EP 0479897 A	15-04-1992
		IE 902389 A	19-06-1991
		JP 4506454 T	12-11-1992
		WO 9100296 A	10-01-1991
		US 5234820 A	10-08-1993

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.